1. Pharma packaging turnaround - The pharma packaging business is expected to achieve PBILDT breakeven in H2FY25, and management expects consolidation to generate annual savings of \~₹5-6 crore from FY26. With FY26 revenue of ₹70.3 crore and a ₹1,377 crore addressable market growing at 9-10%, a shift from loss to contribution directly lifts consolidated EBITDA.
2. LabQuest instrumentation scale-up - Lab Equipment sales grew 25.6% YoY to ₹53.1 crore in FY26, building on 32.3% growth in FY25, from a single-digit market share in a ₹4,800 crore market. The segment is already past proof-of-concept and now adds operating leverage on a fixed-cost engineering base.
3. GSGWL integration and rights issue - Borosil Scientific invested ₹11.68 crore in Goel Scientific Glass Works in November 2025, raising its stake to 99.37%, to fund capital and operational expenses. GSGWL losses narrowed in FY25 and the unit hit PBILDT breakeven in H1FY25, so incremental orders now flow through to profit rather than covering overheads.
4. US tariff reversal and trade deals - US tariff reversal is expected to propel the high-margin export business forward, with additional tailwinds from India-US and India-EU trade deals. Exports reach over 90 countries, and lower trade friction expands the addressable premium market for lab glassware where Borosil already holds OEM relationships.
5. Filter paper and new consumables - A major investment is underway to upgrade filter paper production, opening a new category for innovation and market expansion. Filter paper is a recurring-use consumable adjacent to existing lab glassware, pulling through the same distributor network of 150+ channel partners.
6. Biopharma SHAKTI policy catalyst - The launch of Biopharma SHAKTI in the Union Budget 2026-27 is expected to drive demand for products used in biologics and biosimilars. Borosil’s process systems and pharma packaging verticals supply precisely the R&D and production infrastructure that biopharma expansion requires.
7. Operational efficiency and Nashik VRS - A Voluntary Retirement Scheme at the Ambad, Nashik plant (₹6.61 crore exceptional item in FY26) and enhanced production efficiency improved standalone EBITDA in FY26. The one-time cost removes a structural drag, and the resulting lower fixed-cost base amplifies margin gains as pharma packaging volumes grow.